早期YAG激光玻璃体消融术治疗症状性玻璃体混浊的疗效与安全性:一项随机临床试验的研究方案
本研究为随机、对照、双盲临床试验,计划前瞻性招募70例症状性玻璃体混浊病程1个月的受试者,随机分为早期治疗组与延迟治疗组各35例。早期治疗组立即接受YAG激光玻璃体消融术并于3个月后接受假激光,延迟治疗组先接受假激光并于3个月后接受YAG激光玻璃体消融术,随访至随机后12个月,主要结局为自报视觉干扰改善评分(1至10分)与NEI VFQ-25评分。
要点
- 随机、对照、双盲试验,早期组35例立即YAG激光后3个月假激光,延迟组35例先假激光后3个月YAG激光。
- 主要结局为自报视觉干扰改善评分(1至10分)与NEI VFQ-25评分,随访时间点为随机后1、3、6、12个月。
- 次要结局通过OCT与眼底照相客观评估玻璃体混浊减少效果,并追踪眼部或整体健康相关不良事件。
核心结论
- 本试验旨在评估YAG激光玻璃体消融术治疗症状性玻璃体混浊的有效性,并评估早期干预的安全性。
研究设计与样本
- 随机、对照、双盲临床试验,前瞻性招募70例症状性玻璃体混浊病程1个月的受试者。
- 受试者随机分为早期治疗组与延迟治疗组,每组35例。
- 早期治疗组立即接受YAG激光玻璃体消融术,3个月后接受假激光治疗。
- 延迟治疗组先接受假激光治疗,3个月后接受YAG激光玻璃体消融术。
- 随访时间点为随机后1、3、6、12个月。
关键数值与推荐
- 主要结局为受试者自报视觉干扰改善评分(1至10分)与NEI VFQ-25评分。
- 次要结局为通过OCT与眼底照相客观评估玻璃体混浊减少效果,并追踪眼部或整体健康相关不良事件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vitreous floaters are a common ocular condition that affects individuals of all ages. Although vitreous floaters are typically benign, they can significantly impair visual acuity and quality of life. Laser vitreolysis, which uses an Nd: YAG laser to vaporize collagenous vitreous opacities, is increasingly being used as a treatment option. However, there is currently a lack of evidence regarding its efficacy and the appropriate timing of its application. This study aims to evaluate the efficacy and safety of early intervention with YAG laser vitreolysis in treating symptomatic vitreous floaters. METHODS: The present study is a randomized, controlled, double-blind clinical trial. A total of 70 participants with symptomatic floaters for 1 month were prospectively recruited. These participants will be randomly assigned to two groups, with 35 individuals in each group: the early treatment group and the delayed treatment group. Participants assigned to the early treatment group will undergo YAG laser vitreolysis immediately, followed by a sham laser treatment 3 months later. On the other hand, participants assigned to the delayed treatment group will receive a sham laser treatment and then undergo YAG laser vitreolysis 3 months later. The follow-up time points will be 1, 3, 6, and 12 months from randomization. Primary outcomes will be participants' self-reported improvement in visual disturbance on a scale of 1 to 10 and their scores on the National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25). Secondary outcomes will be an objective evaluation of the effectiveness of the treatment in reducing vitreous floaters through OCT and fundus photography and tracking any adverse events related to the eyes or overall health. DISCUSSION: This clinical trial aims to evaluate the effectiveness of YAG laser vitreolysis in treating symptomatic vitreous floaters and assess the safety of performing early intervention with YAG laser vitreolysis. TRIAL REGISTRATION: ClinicalTrials.gov NCT05800353 . Registered on 10 March 2023.
引用
- Hangshuai Z, Yanhua J, Yao Z, et al. Efficacy and safety of early YAG laser vitreolysis for symptomatic vitreous floaters: the study protocol for a randomized clinical trial. Trials. 2024. PMID: 38218919. doi:10.1186/s13063-024-07924-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。